[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psa-psoriatic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psa-psoriatic-arthritis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100617164","phase-2-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-d-2570-in-subjects-with-active-psoriatic-arthritis-100617164",false,"NCT07315061","A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis","Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis","D2570-204","Inclusion Criteria:\n\n1. Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;\n2. Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;\n3. Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;\n4. Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).\n\nExclusion Criteria:\n\n1. History of infection as defined in the protocol;\n2. Any of the medical diseases or disorders listed in the protocol;\n3. Significant, uncontrolled or unstable disease in any organ.","ALL","18 Years","70 Years",{"count":21,"type":22},222,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.",[28],"PsA (Psoriatic Arthritis)",[28],"RECRUITING","2026-04-21",{"date":33,"type":34},"2026-04-22","ACTUAL",{"date":36,"type":34},"2026-01-16",{"date":38,"type":22},"2028-08-06",{"name":40,"class":41},"InventisBio Co., Ltd","INDUSTRY"]